Mayo Clinic in Rochester, Minn., Mayo Clinic in Phoenix/Scottsdale, Ariz., and Mayo Clinic in Jacksonville, Fla., are ranked among the Best Hospitals for cancer by U.S. News & World Report.
Mayo Clinic in Rochester, Minn., ranks No. 1 for digestive disorders in the U.S. News & World Report Best Hospitals rankings. Mayo Clinic in Phoenix/Scottsdale, Ariz., and Mayo Clinic in Jacksonville, Fla., are ranked among the Best Hospitals for digestive disorders by U.S. News & World Report. Mayo Clinic also ranks among the Best Children's Hospitals for digestive disorders.
Below are current clinical trials.3 studies in Colon and Rectal Surgery
(open studies only).
Filter this list of studies by location, status and more.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and important part of treatment for rectal cancer and has been shown to decrease the risk of the cancer coming back in the same area in the pelvis, some patients experience undesirable side effects from the radiation and there have been important advances in chemotherapy, surgery, and radiation which may be of benefit. The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.
The purpose of this study is to examine the needs and gap in our understanding of financial burden experienced by rectal cancer patients from a patient perspective to help provide patient centered care and improve psychosocial outcomes of this group.
The purposes of this study are to characterize the microbes that are causal of colorectal cancer and those that are merely conditions of the tumor. This will be accomplished by comparing the microbiomes before and after resection. Secondly, to pilot a study to differentiate between the effect of resection versus the effect of tumor removal by comparing microbiomes in two cohorts: colorectal cancer patients and controls from benign colon resection. Finally, to understand what confers community-level microbial stability or resilience in a colorectal cancer patient. This pilot study will be accomplished by sampling stool samples from patients longitudinally, and then using advance bioinformatics and statistical learning techniques to identify features predictive of gut microbial ecological properties.
Oct. 11, 2019